Gastrointestinal involvement in systemic sclerosis: an update.
Gastrointestinal involvement in systemic sclerosis: an update.
复制标题
DOI：
10.1097/bor.0000000000000645
复制
发表时间：
2019-11
影响因子：
5.1
通讯作者：
中科院分区：
文献类型：
--
作者：
这篇综述提供了系统性硬化症（SSc）相关胃肠道（GI）疾病的重要更新，特别关注最近的文献。在过去的一年中，发表了几项研究，对SSc和GI疾病提出了有趣的见解。针对新发现的风险因素、诊断和评估疾病活动性、生存率和生活质量的新方法的研究表明，我们对这一具有挑战性的领域的理解取得了进展。关于特定SSc GI相关主题的其他数据，例如GI与肺部疾病，营养和微生物组之间的联系，现在也可以获得。SSc GI疾病的临床表现具有异质性，这对诊断和管理提出了挑战。在过去的一年中，几项研究评估了与SSc特定GI并发症相关的风险因素和临床特征。目的GI检测可能有助于识别特定的SSc GI亚组，并提供诊断准确性，以指导靶向治疗。极早期SSc的生存率受GI受累严重程度的影响。存在其他重要的GI亚组，包括食管疾病和间质性肺病患者，在为该患者人群制定管理计划时应仔细考虑。
This review provides important updates in systemic sclerosis (SSc)-related gastrointestinal (GI) disease, specifically focusing on the most recent literature. In the past year, several studies were published that present interesting insights into SSc and GI disease. Studies focusing on newly identified risk factors, novel approaches to diagnosis and assessment of disease activity, survival and quality of life demonstrate progress in our understanding of the challenging area. Additional data on specific SSc GI-related topics, such as the link between GI and pulmonary disease, nutrition, and the microbiome, are also now available. SSc GI disease is heterogeneous in its clinical presentation, which presents a challenge in diagnosis and management. In the past year, several studies have evaluated risk factors and clinical features associated with specific GI complications in SSc. Objective GI testing may help to identify specific SSc GI subgroups and provide diagnostic accuracy to guide targeted therapies. Survival in very early SSc is affected by the severity of GI involvement. Other important GI subsets exist, including patients with esophageal disease and interstitial lung disease, should carefully be considered when developing a management plan for this patient population.